Rafferty Asset Management
KPTI icon

Rafferty Asset Management’s Karyopharm Therapeutics KPTI Stock Holding History

Rafferty Asset Management’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-60,887
Closed -$3.55M – 1117
2023
Q1 		$3.55M Buy
60,887
+14,443
+31% +$713K 0.02% 470
2022
Q4 		$2.37M Buy
46,444
+1,910
+4% +$132K 0.02% 531
2022
Q3 		$3.65M Buy
44,534
+13,907
+45% +$1.04M 0.04% 384
2022
Q2 		$2.07M Sell
30,627
-23,302
-43% -$2.14M 0.02% 453
2022
Q1 		$5.96M Buy
53,929
+28,558
+113% +$3.56M 0.04% 332
2021
Q4 		$2.45M Buy
25,371
+639
+3% +$63.7K 0.01% 590
2021
Q3 		$2.16M Buy
24,732
+7,881
+47% +$818K 0.01% 622
2021
Q2 		$2.61M Sell
16,851
-1,193
-7% -$173K 0.02% 576
2021
Q1 		$2.85M Buy
18,044
+14,115
+359% +$2.97M 0.02% 524
2020
Q4 		$912K Sell
3,929
-5,386
-58% -$1.25M 0.01% 530
2020
Q3 		$2.04M Buy
9,315
+5,503
+144% +$1.35M 0.02% 410
2020
Q2 		$1.08M Buy
3,812
+2,984
+360% +$883K 0.02% 521
2020
Q1 		$239K Sell
828
-6,216
-88% -$1.71M 0.01% 485
2019
Q4 		$2.02M Sell
7,044
-6,063
-46% -$1.32M 0.03% 388
2019
Q3 		$1.89M Buy
+13,107
New +$1.78M 0.03% 403

Other funds holding KPTI

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
ECM
ExodusPoint Capital Management New York $12.6B AUM 30.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Rafferty Asset Management's KPTI Position: Q2 2023 in Review

Rafferty Asset Management sold out of Karyopharm Therapeutics (KPTI) in Q2 2023, closing a stake of 60,887 shares — an estimated $3.55M sold.

Rafferty Asset Management first reported a position in KPTI in Q3 2019 and held it in 15 quarters. The position peaked at $5.96M in Q1 2022. 137 funds tracked by Wall St. Rank hold KPTI as of Q2 2023.

  • Rafferty Asset Management reported no remaining Karyopharm Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Rafferty Asset Management sold 60,887 Karyopharm Therapeutics shares in Q2 2023, an estimated $3.55M.
  • Rafferty Asset Management first reported a position in Karyopharm Therapeutics in Q3 2019 and held it in 15 quarters.
  • Rafferty Asset Management's Karyopharm Therapeutics position peaked at $5.96M in Q1 2022.
  • 137 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q2 2023.

Based on Rafferty Asset Management's 13F filing for Q2 2023, filed 11 Aug 2023.